IndraLab
Statements
sparser
"In our own solution biophysical studies, we observed weak heterodimerization of ErbB2 with the neuregulin-bound extracellular regions of ErbB3 or ErbB4 [ xref ], but failed to detect EGF-induced association of the EGFR and ErbB2 extracellular regions (or other anticipated heterodimers)."
sparser
"Additionally, AFM was also applied to investigate the effect of Trastuzumab, as well as Pertuzumab, on HER2-modulated EGF-EGFR interactions, which demonstrated that EGF bound to EGFR more stably in the cells co-expressing EGFR and HER2, and the binding enhancement in the presence of HER2 was inhibited by either Trastuzumab or Pertuzumab [ xref ]."
sparser
"In this manuscript we demonstrate through combination of scattering spectroscopy, electron microscopy, and generalized multiple particle Mie theory (GMT) simulations that the density- and morphology-dependent spectral response of Au nanoparticle (NP) immunolabels bound to the epidermal growth factor receptors ErbB1 and ErbB2 encodes quantitative information of both the cell surface expression and spatial clustering of the two receptors in different unliganded in vitro cancer cell lines (SKBR3, MCF7, A431)."
sparser
"Living-cell single-molecule force spectroscopy (SMFS) combined by Atomic Force Microscopy (AFM) was used by this team of scientists to investigate the effect of two monoclonal antibodies used in cancer therapy, Trastuzumab and Pertuzumab, on HER2-modulated EGF-EGFR interaction, demonstrating the utility of this technique in characterizing the effects of protein-based therapeutics on membrane receptors."
sparser
"Results from co-immunoprecipitation experiments and western blot analyses indicate that tyrosine-phosphorylated ErbB2 and EGFR monomers and stable ErbB2/EGFR high molecular complexes (heterodimers) are formed following EGF stimulation, even if the receptors co-immunoprecipitates also in the absence of the ligand; these data suggest the existence of pre-dimerization inactive receptor clusters on the cell surface."
sparser
"The monoclonal antibodies cetuximab and trastuzumab, which bind to the epidermal growth factor receptors EGFR and HER-2, respectively, were chosen because they are already established targeting vectors to deliver radioactive isotopes and fluorescent dyes separately. xref - xref EGFR and HER2 are expressed/over-expressed in a variety of cancer cell lines."